Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) saw unusually-strong trading volume on Friday . Approximately 91,944 shares were traded during trading, a decline of 25% from the previous session’s volume of 122,916 shares.The stock last traded at $16.78 and had previously closed at $16.73.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TYRA shares. HC Wainwright restated a “buy” rating and set a $23.00 target price (up from $19.00) on shares of Tyra Biosciences in a report on Wednesday. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Thursday. Finally, Bank of America downgraded Tyra Biosciences from a “buy” rating to a “neutral” rating and lowered their price target for the company from $25.00 to $15.00 in a report on Friday, December 15th.

Tyra Biosciences Price Performance

The business has a 50 day simple moving average of $17.09 and a 200 day simple moving average of $14.55. The stock has a market cap of $878.13 million, a PE ratio of -10.39 and a beta of 1.19.

Insider Transactions at Tyra Biosciences

In other news, COO Daniel Bensen sold 1,501 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $20.00, for a total transaction of $30,020.00. Following the completion of the sale, the chief operating officer now owns 451,480 shares in the company, valued at approximately $9,029,600. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 15,816 shares of company stock worth $298,165. 18.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several large investors have recently made changes to their positions in TYRA. UBS Group AG raised its holdings in Tyra Biosciences by 3,841.8% in the 4th quarter. UBS Group AG now owns 3,587 shares of the company’s stock valued at $27,000 after acquiring an additional 3,496 shares in the last quarter. Barclays PLC raised its holdings in Tyra Biosciences by 544.1% in the 4th quarter. Barclays PLC now owns 3,581 shares of the company’s stock valued at $27,000 after acquiring an additional 3,025 shares in the last quarter. Simplex Trading LLC raised its holdings in Tyra Biosciences by 198.1% in the 3rd quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after acquiring an additional 1,335 shares in the last quarter. Federated Hermes Inc. raised its holdings in Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after acquiring an additional 1,916 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in Tyra Biosciences by 206.9% in the 2nd quarter. Royal Bank of Canada now owns 2,277 shares of the company’s stock valued at $39,000 after acquiring an additional 1,535 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies.